Intranasal Insulin for Weight Management During Smoking Cessation
Status: | Completed |
---|---|
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 12/12/2018 |
Start Date: | July 2014 |
End Date: | May 2016 |
This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in
reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.
reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.
Inclusion Criteria:
- smokers (>10 cig/day) for the past 1 year
- normosmic olfactory function
Exclusion Criteria:
- previous/current use of insulin
- current Diagnostic and Statistical Manual-IV-Revised (DSM-IV-R) Axis I disorder
- current pregnancy (or lactation)
- lifetime history of endocrine disease
- excessive alcohol use (>25 standard units of alcohol/week)
- current use of illicit drugs
- current use of a smoking cessation aid (NRT, Chantix or Wellbutrin), or a psychotropic
agent
- local infections, inflammation, structural abnormalities, or other nasal pathology
- current use of any medications administered intranasally, including intranasal
steroids
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials